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Summary We have discovered modified fucosylation of ac1-antitrypsin (F-AT) in the sera of ovarian cancer
patients. This was detected by SDS/electrophoresis and silver-staining after extracting the sera with the
fucose-binding lectin, Lotus tetragonolobus, and was identified as x1-antitrypsin by Western blotting. Initially,
high F-AT levels appeared to be related to the recurrence of cancer, but later measurements showed that
elevated levels were also present in patients who did not respond to therapy. Using an arbitrary grading
system, the level of F-AT was assessed in pairs of sera from 29 ovarian cancer patients undergoing therapy;
one specimen collected just after the start of therapy and the other on a later occasion. In 75% of the 15 non-
responders, F-AT was higher when measured on a second occasion; whereas in 86% of the 14 responders the
second measurement was either unchanged or lower, being frequently undetectable. F-AT levels were also low
or undetectable in sera from healthy women. Eight responders were monitored for F-AT throughout
cyclophosphamide chemotherapy. Despite a high tumour burden at the start of therapy, all patients had
relatively low levels of F-AT and this was maintained throughout remission; the levels only becoming elevated
with the recurrence of tumour growth. Increased F-AT expression did not appear to be particularly associated
with the presence of liver metastases and frequently predated any clinical signs of a recurrence. The
interesting characteristics of these molecules could make them useful in the management of ovarian cancer.
Serum protein-bound fucose is often elevated in cancer sera
(Turner et al., 1985) and it has been previously suggested
that it may be useful as a cancer marker (Evans et al., 1974;
Waalkes et al., 1978; Turner et al., 1985). The source of this
change is unknown. Using a fucose-specific lectin (Lotus
tetragonolobus), we recently extracted and identified an
abnormal form of haptoglobin that was elevated in sera
from a wide-range of cancer patients (Thompson & Turner,
1987a). The level of expression of this molecule was related
to tumour burden (Thompson & Turner, 1987b). Whilst using
Lotus extraction to analyse serial serum specimens from
ovarian cancer patients who were receiving chemotherapy, it
was noticed that the level of other extracted components (56/
58 kD) varied in a most unusual way. In contrast to the
extracted haptoglobin, these new molecules appeared to vary
in relation to tumour progression rather than tumour
burden. We herein report these findings, identify these
components and present evidence to suggest that they could
be very useful for monitoring response to therapy. Some of
the results have already been presented as a preliminary
report (Thompson et al., 1987a).
Patients and methods
Patienits and sera
Blood specimens were obtained from 9 healthy women
(median age=55 yr; range 44-65) and 29 women with ovar-
ian cancer (median age = 54 yr; range 41-69) by vene-
puncture. Sera were separated by low speed centrifugation
for 10min and were stored at -20 C until required for
analysis. All cancers were diagnosed by laparotomy (stages
III/IV) and confirmed by histology (serous or mucinous
cystadenocarcinoma). At laparotomy, different amounts of
tumour were removed, but in every case tumour remained in
the abdomen. Cyclophosphamide chemotherapy was started
I week after laparotomy (Guthrie, 1979). Eight cancer
patients provided serial specimens at various times through-
out their chemotherapy. Some patients showed clinical evi-
dence of tumour remission followed by recurrence of tumour
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growth; whereas other patients did not show any evidence of
clinical remission. All patient assessments were made by
abdominal, vaginal and rectal examination, together with
ultrasound and radiological investigations where appropriate.
Remission and recurrence were as previously defined (Turner
et al., 1982).
Extraction and analysis offucoproteins
These methods have been extensively described elsewhere
(Thompson & Turner, 1987b; Thompson et al., (1987b).
Briefly, a fucose-binding lectin (Lotus tetragonolobus,
Sigma) was coupled to CNBr-activated Sepharose beads
(Pharmacia) at 2 mgml- l beads. Fucoproteins were
extracted from 100 kd aliquots of serum by mixing with
lOO1k Lotus lectin-beads for I h at room temperature.
Unbound proteins were washed away and bound fuco-
proteins were eluted from the beads with 50-100kl of the
electrophoresis sample buffer (125 mmol 1- 1 Tris-HCl,
pH 6.8, 2.7mol l I glycerol, I mmol 1- 1 EDTA) containing
0.35 mol- 1 sodium dodecyl sulphate (SDS). The bound
molecules could be eluted with 0.5moll-I fucose but SDS
was used routinely because it eluted all components in larger
amounts. The fucoproteins (10-15,u1 of extract) were then
separated by 1-dimensional SDS-polyacrylamide gel electro-
phoresis in discontinuous 8% (w/v) polyacrylamide slab gels.
A silver staining procedure was used to visualise the separ-
ated proteins (Thompson, 1987). Western blotting was
carried out by the method of Blake et al. (1984) with rabbit
anti-x1-antitrypsin (Behring) as the first layer antibody (1/
1,000 dilution) and alkaline phosphatase conjugated sheep
anti-rabbit immunoglobulins (Serotec) as the second layer.
Two-dimensional polyacrylamide gel electrophoresis (2D-
PAGE) was carried out as previously described (Thompson
& Turner, 1987b). Data was analysed statistically using
either the Mann-Whitney test or a paired Wilcoxon analysis.
Results
Figure 1 shows the patterns obtained after the electro-
phoretic separation of lectin-extracted serum proteins from
two ovarian cancer patients who were receiving chemo-
therapy. Blood specimens were taken on 6 and 4 occasions
respectively: I or 2 at the start of chemotherapy when
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band I
43-
Tumour * + + - - + +
Days 14 21 77193485506
+ - - +
0 38 142 354
Figure 1 The electrophoretic separation of Lotus-extracted sera
from 2 women with ovarian cancer. Specimens were collected
throughout cytotoxic chemotherapy. In Figures 1-3, the presence
of clinically-detectable tumour and the time after the start of
therapy are indicated below the separations. In Figures 1-4, the
58 kD fucoprotein is indicated by a large arrow-head on the right
hand side of the gel. Red blood cell proteins (78, 72, 43, 35 and
29kD) were used as molecular weight markers and the position
of these is given at the side of each figure.
tumour burden was high; 2 during clinical remission when
tumour burden was low; and finally 1 or 2 when a recur-
rence of tumour growth had occurred. Several consistent
changes can be seen during therapy, but a very noticeable
one is a large increase in a broad band at -56/58 kD at
tumour recurrence. Surprisingly, these components are rela-
tively weakly expressed at the start of therapy, despite large
amounts of tumour being present.
Other changes in the patterns in Figure 1 can be seen,
some of these are reported elsewhere (Thompson & Turner,
1987b). The band at 43kD, which is the fl-chain of hapto-
globin, is weaker than previously reported (Thompson &
Turner, 1987b). This is because, in order to resolve the
components at 56/58kD; less extract was separated (10pu
instead of 25p1) and the stain was developed for a shorter
time. There is also a heavy band at 76kD, which disappears
at tumour recurrence. If this component can be identified, it
will be the subject of a separate report in the near future.
The 56/58kD band was identified by the data given in
Figure 2. This shows electrophoretic separations of serum
extracts from a third ovarian cancer patient (a) silver-stained
for protein and (b) blotted for the presence of a -antitrypsin
(AT) using an anti-AT antibody. The only band on the
Western blot is a band that correlates in intensity and
position with the 56/58 kD band in the silver-stained pattern.
It is interesting to note that both blotting and protein
staining detect a band before any tumour recurrence was
clinically detected. Its identity as AT was confirmed by 2D-
PAGE (data not shown), because its position in the 2D-
pattern was similar to that previously reported for AT
(Tracy et al., 1982).
Elevated levels of the fucosylated o1-antitrypsin (F-AT)
were also found in extracts of sera from ovarian cancer
patients who did not respond to chemotherapy. Typical
examples of this are shown by the patterns given in Figure 3.
These show the results for pairs of specimens from three
patients; the first specimen being provided within 14 days of
the start of therapy and the other specimen at a later time.
In two of these specimens, F-AT runs as two bands. This
type of pattern was only seen occasionally, but it was a
consistent finding that was not related to a particular batch
wiIver
Tumour > + - - + +
Days 24 88 228 284 417
Blot
Figure 2 A comparison of a silver stained electrophoretic pat-
tem with an anti-o -antitrypsin Western blot for the same series
of extracts. Sera were collected from a woman with ovarian
cancer who was being treated with chemotherapy.
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Figure 3 The electrophoretic separation of pairs of serum
extracts from 3 women who did not respond to chemotherapy.
The first specimen was collected within 14 days of the start of
therapy and the second specimen on a later occasion.
of lectin reagent, and both bands always blotted for AT
(data not shown).
Using an arbitrary grading system from 0 to 5, a blind
assessment was made by two investigators of F-AT levels in
serum-extracts from 29 women with ovarian cancer (Table I).
An increase in the grade by 1 represents approximately a
doubling in the intensity of the F-AT band. Two specimens
were analysed for each patient (one at the start of therapy
and one at a later date). The patients are shown as two
groups; those who did not respond to therapy (non-
responders) and those who had a complete clinical remission
(responders). At the start of therapy, there was no difference
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Table 1 Serum F-AT levels in responding and non-responding
ovarian cancer patients.
Intensity of F-AT band (grade)
1 2 3 4 5 6 7
P.- , -- --i-- - s
Non-responders
Specimen
1 2 Change
4
2
2
0
4
2
3
0
1
2
1
0
0
2
4
3
3
4
3
4
1
2
4
2
2
0
2
1
D
I
I
I
N/C
I
N/C
I
N/C
I N/C
Responders
Specimen
1 2 Change
(81)
(147)
(53)
(114)
(24)
(168)
(41)
(31)
(21)
(49)
(21)
(35)
(35)
(62)
(28)
2
0
1
2
2
1
0
0
1
3
4
0
2
0
2
0
1
0
1
0
0
0
1
0
1
0
3
D
N/C
N/C
N/C
D
D
D
N/C
N/C
N/C
D
D
N/C
I
(45) 1 0
Responders specimen 1 vs. 2, P>0.05, Non-responders specimen 1
vs. 2, 0.05>P>0.002 (Wilcoxon paired analysis).
D, I and N/C=decrease, increase and no change respectively.
Values in parenthesis are the number of days between specimens 1
and 2.
Specimen 1 was obtained within 14 days of starting
chemotherapy.
in the median grading of both groups, but after a period of
therapy the F-AT levels were very different. In the non-
responders, 75% of the women had significantly higher levels
of F-AT in their second specimen than in the first specimen
(0.05>P>0.02; paired Wilcoxon). In the responders, the F-
AT level was either very low in both specimens or was lower
in the second specimen; but this difference in expression was
not statistically significant (P>0.05). F-AT was undetectable
(grade=0) in 8/14 of the responders when measured on a
second occasion (see Table I).
Very low levels of F-AT were also detected in some sera
from age-matched healthy individuals (Figure 4). In a group
of 9 women (only 6 shown on the figure), individuals were
graded as either 0 or 1. For the purposes of comparison, a
serum extract from a patient with a recurrent ovarian cancer
was also separated with the 'healthy' serum extracts.
Figure 5 shows the serum F-AT levels in 8 patients who
were monitored at various times throughout their chemo-
therapy. All these patients responded to chemotherapy, had
a period of clinical remission, followed by recurrence of
tumour growth. To allow comparison between patients, F-
AT expression is given as a grading. The patients are
ordered according to the staging of their disease and the
amount of tumour removed at laparotomy ('C' most of the
tumour remained; 'B' >50% of the tumour removed). With
patients (e-h) the presence of liver metastases were noted on
the surgical report ('L'). The electrophoretic patterns for
three of the patients (e, g and h) have already been shown in
Figures 1 and 2. For all the patients investigated in this way,
the pattern of change was similar to that previously des-
cribed, i.e. low, falling or undetectable levels of F-AT in
remission and higher or rising levels during recurrence. The
pattern of F-AT expression was not correlated with the stage
of the disease or the presence of residual tumour after
laparotomy. Also, patients who had liver metastases did not
have higher levels of F-AT when they had a recurrence of
tumour growth. In five patients, F-AT fell to undetectable
levels during remission, and in half the patients, increases in
F-AT predated any clinical symptoms of tumour recurrence.
(37) Figure 4
from six
recurrent
The electrophoretic separations of 101d serum extract
healthy women (lanes 1-6) and one patient with
ovarian cancer (lane 7).
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Figure 5 An assessment of the expression of F-AT in serum
extracts from 8 women who were undergoing treatment for
ovarian cancer. The intensity of the F-AT is given as an
arbitrary grade. The presence of clinically-detectable tumour and
the time after start of chemotherapy are shown below the figure
respectively. If F-AT was undetectable this is shown as a *. The
Roman numerals indicate the stage of the disease at the start of
therapy and the proceeding letter indicates the amount of
tumour removed at laparotomy ('B' > 50% removed; 'C' most of
the tumour not removed). The superscript 'L' indicates the
detection of liver metastases.
Discussion
The abnormal forms of AT we isolated from the blood of
ovarian cancer patients was a surprising finding because they
appeared to be only present in high amounts when there was
78-
72
43-
(7)
(38)
(119)
(17)
(64)
(134)
(218)
(63)
(14)
(18)
(21)
(14)
(35)
(35)
Median 1 3
35-
29-
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a recurrence of tumour growth. This suggested that they may
be useful for predicting patient response to therapy. This was
shown to be the case, but in order for them to have any real
predictive value, it was necessary to measure F-AT in two
blood specimens. One specimen to be collected at the start of
therapy and the other specimen at a later date. Using this
approach the majority of responding and non-responding
patients could be discriminated. This discrimination would
probably be made even more complete if F-AT was esti-
mated in more than two specimens, and specimens could
have been collected prior to the start of therapy.
The source of F-AT is unknown, the liver is the most
likely candidate, as this organ is the major site for the
synthesis of AT under normal circumstances (Laurell &
Jeppsson, 1975). The presence of liver metastases could
affect AT synthesis. Abnormally glycosylated AT has been
shown to be synthesized by human hepatoma cells in culture
(Carlson et al., 1984). The situation is still unclear, because
the presence of liver metastases did not seem to effect F-AT
levels. Other sources of F-AT are possible, including the
tumour itself, but we have so far failed to detect any AT in
cultured ovarian cancer cells (unpublished observations).
Although the F-AT levels in the healthy sera used in this
study were either very low or undetectable, we have also
found in other studies, that younger women (median
age=37y) have slightly higher levels (grades 1-2). As the
majority of the women we used were post-menopausal, this
suggests that F-AT could be affected by oestrogen levels. It
is known that these substances can elevate total AT levels in
the blood (Laurell & Rannevik, 1979). Further work is
necessary to clarify this aspect.
Without further investigations it is difficult to understand
the nature of the change that is occurring in AT in cancer.
Lotus specificity is directed towards fucose that is linked in
either a a-(l-2) position in sub-terminal galactose or in a a-
(1-6) position to a N,N'diacetylchitobiose core (Petryniak &
Goldstein, 1986). In early work, fucose was reported to be
present in AT in very low amounts (Heimburger et al., 1964;
Crawford, 1973; Chan, Luby and Wu, 1973), but in more
recent investigations, this finding has not been confirmed
(Mega et al., 1980; Hodges & Chan, 1982). The precise
nature and number (3 or 4) of the carbohydrate sidechains
on AT is also controversial (Mega et al., 1980; Hodges &
Chan, 1982; Bayard et al., 1982). All studies find bi- and tri-
antennary oligosaccharides and some have reported the
absence of sialic acid on some units (Hodges & Chan, 1982;
Bayard et al., 1982; Hercz, 1984). The possibility that fucose
could be added to existing sidechains of AT in cancer is not
unfeasible.
The nature of F-AT varied from sera to sera, sometimes it
was one diffuse band at 58kD; whereas at other times there
were two bands 56 and 58 kD. Non-extracted AT has
reportedly a Mr of between 50 and 55 kD (Laurell &
Jeppsson, 1975), we have found an average Mr of 55kD for
AT using our SDS/PAGE system (unpublished obser-
vations). The higher Mr of F-AT is probably an overall
reflection of changed AT glycosylation (e.g. increased gly-
cans or increased branching), of which increased fucosylation
is one part of this process. As well as increasing the absolute
Mr' these changes could also decrease the amount of SDS
bound, so reducing the electrophoretic mobility and increas-
ing the apparent Mr. The abnormally-glycosylated AT found
by Carlson et al. (1984) had a higher Mr (56kD).
It seems likely that the difference in F-AT between
'responders' and 'non-responders' reflects differences in
tumour progression rather than differences in tumour
growth, because both groups had similar amounts of tumour
at the start of chemotherapy. In the 'non-responders', this
change in tumour properties has already occurred before the
start of treatment; whereas in the 'responders', it occurs
when the tumour regrows. The ability to spread to the liver
would seem to be the most likely property that the tumour
could acquire to affect AT synthesis, but as already stated,
there is no evidence to link F-AT levels and liver metastasis.
Also, if the presence of tumour in the liver is affecting
protein glycosylation, it is difficult to explain why the levels
of fucosylated haptoglobin (F-Hp) are related to tumour
burden (Thompson & Turner, 1987b) and not tumour pro-
gression. Possibly there are further changes in the properties
of the tumour when it is well established in the liver, and
this could explain the discrepancies between F-AT and
F-Hp.
The predictive value of serum F-AT level could make it
very useful in the routine biochemical screening of ovarian
cancer. All current markers for this disease, including fuco-
sylated haptoglobin, are only indicators of tumour burden,
confirming an already established clinical diagnosis.
Measurement of F-AT could greatly improve this situation
and allow clinicians to make earlier changes in their thera-
peutic strategy, so improving patient survival and reducing
the costs of patient care. Much further work is required to
investigate the general applicability of this test to different
treatment regimes, to the interference by non-cancerous
conditions and to cancers arising in other sites. In addition,
a method is being developed to measure F-AT using lectin
bound to multi-well plates. This will considerably speed-up
the assay and so make it more attractive for using in a
routine hospital laboratory.
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